Drug intelligence / Profile preview

metoclopramide + diphenhydramine

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Oral

Overview

A combination of two medications used primarily for antiemetic purposes. Metoclopramide is a dopamine D2 receptor antagonist and serotonin 5-HT3 receptor antagonist with prokinetic effects that enhance gastric emptying. Diphenhydramine is a first-generation histamine H1 receptor antagonist with antimuscarinic properties. Together, they provide enhanced antiemetic effects while diphenhydramine helps counteract some of metoclopramide's extrapyramidal side effects.

Targets

HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)HTR3A (5-hydroxytryptamine receptor 3A)HTR4 (5-Hydroxytryptamine receptor 4)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on metoclopramide + diphenhydramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoclopramide + diphenhydramine.

Explore the full profile